

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Methylergometrine maleate

March 17, 2026

### **Therapeutic category**

Oxytocics

### **Non-proprietary name**

Methylergometrine maleate

### **Safety measure**

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
 This English version is intended to be a reference material to provide convenience for users.  
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: HIV protease inhibitors (preparations containing ritonavir, atazanavir sulfate, fosamprenavir calcium hydrate, preparations containing darunavir ethanolate), efavirenz, azole antifungal agents (itraconazole, voriconazole, posaconazole), preparations containing cobicistat, nirmatrelvir/ritonavir, letermovir, ensitrelvir fumaric acid, lenacapavir sodium, 5-HT1B/1D receptor agonists (sumatriptan, zolmitriptan, eletriptan hydrobromide, rizatriptan benzoate, naratriptan hydrochloride), ergotamine tartrate/anhydrous caffeine/isopropylantipyrine</p>			<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: HIV protease inhibitors (preparations containing ritonavir, atazanavir sulfate, fosamprenavir calcium hydrate, preparations containing darunavir ethanolate), efavirenz, azole antifungal agents (itraconazole, voriconazole, posaconazole), preparations containing cobicistat, nirmatrelvir/ritonavir, letermovir, ensitrelvir fumaric acid, lenacapavir sodium, 5-HT1B/1D receptor agonists (sumatriptan, zolmitriptan, eletriptan hydrobromide, rizatriptan benzoate, naratriptan hydrochloride), ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, <u>ceritinib</u></p>		
<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>			<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
HIV protease inhibitors Preparations containing ritonavir Atazanavir sulfate Fosamprenavir calcium hydrate	The blood concentration of this drug may increase, which may cause serious adverse reactions	The metabolism of this drug may be suppressed by CYP3A4 inhibition due to these drugs.	HIV protease inhibitors Preparations containing ritonavir Atazanavir sulfate Fosamprenavir calcium hydrate	The blood concentration of this drug may increase, which may cause serious adverse reactions	The metabolism of this drug may be suppressed by CYP3A4 inhibition due to these drugs.

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

Preparations containing darunavir ethanolate Efavirenz Azole antifungal agents Itraconazole Voriconazole Posaconazole Preparations containing cobicistat Nirmatrelvir/ritonavir Letermovir Ensitrelvir fumaric acid Lenacapavir sodium	such as angiospasm.		Preparations containing darunavir ethanolate Efavirenz Azole antifungal agents Itraconazole Voriconazole Posaconazole Preparations containing cobicistat Nirmatrelvir/ritonavir Letermovir Ensitrelvir fumaric acid Lenacapavir sodium <u>Ceritinib</u>	such as angiospasm.	
--	---------------------	--	--	---------------------	--

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

Revised language is underlined.